Page last updated: 2024-08-23

raloxifene hydrochloride and Coronary Disease

raloxifene hydrochloride has been researched along with Coronary Disease in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (18.18)	18.2507
2000's	31 (70.45)	29.6817
2010's	5 (11.36)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jordan, VC	4
Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK	1
Amewou-Atisso, MG; Barrett-Connor, E; Collins, P; Dowsett, SA; Effron, MB; Geiger, MJ; Grady, D; Kornitzer, M; Mosca, L; Wenger, NK	1
Wittes, J	1
Badimon, JJ; Choi, BG; Vilahur, G	1
Becker, C	1
Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Slinin, Y	1
Boudjeltia, KZ; Brohée, D; Cauchie, P; Ducobu, J; Durez, P; Gregoir, C; Guillaume, M; Oberweis, D; Remacle, C; Vanhaeverbeek, M	1
Cox, DA; Duvernoy, CS; Kim, HM; Wong, M; Yeo, AA	1
Barrett-Connor, E; Collins, P; Grady, D; Kornitzer, M; Mischke, JM; Mosca, L; Schroeder, K; Schroeder, R; Wenger, NK	1
Nagykálnai, T	1
Anderson, PW; Barrett-Connor, E; Baygani, SK; Collins, P; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Sashegyi, A; Wenger, NK	1
Wenger, NK	2
Hartmann, LC; Riggs, BL	1
Reincke, M	1
Barrett-Connor, E; Cauley, JA; Cox, DA; Geiger, MJ; Kulkarni, PM; Sashegyi, A	1
Hamaya, E; Kobayashi, H	1
Urano, T	1
Geiger, MJ; Wenger, NK	1
Barrett-Connor, E; Cox, DA; Dowsett, SA; Ensrud, K; Geiger, MJ; Genazzani, AR; McNabb, M	1
Barrett-Connor, E; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; McNabb, MA; Mosca, L; Wenger, NK	1
Stefanick, ML	1
Johnson, KA	1
Aumiller, J	1
Agnusdei, D; Barrett-Connor, E; Cauley, JA; Ensrud, KE; Grady, D; Khaw, KT; Mosca, L; Stock, JL; Zhao, Q	1
Anthony, MS; Clarkson, TB; Cline, JM; Williams, JK	1
Fitzpatrick, LA	1
Nelson, NJ	1
Anderson, PW; Barrett-Connor, E; Collins, P; Cox, DA; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Wenger, NK	1
Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB	1
Lush, DT	1
Cohen, F; de Valk-de Roo, GW; Kenemans, P; Kluft, C; Meijer, P; Mijatovic, V; Netelenbos, C; Stehouwer, CD; Watts, S	1
Dayspring, T	1
Dardes, RC; Jordan, VC	1
Anderson, PW; Barrett-Connor, E; Collins, P; Grady, D; Helterbrand, JD; Kornitzer, M; Mosca, L; Moscarelli, E; Paul, S; Wenger, NK; Wright, TJ	1
Gapstur, S; Jordan, VC; Morrow, M	1
Albert, D; Armstrong, K; Chen, TM; Randall, TC; Schwartz, JS	1
Duvernoy, CS; Mosca, L	1
Bentrem, DJ; Craig Jordan, V	1
Grady, D	1

Reviews

13 review(s) available for raloxifene hydrochloride and Coronary Disease

Article	Year
[Selective estrogen receptor modulators (SERMs) in the practice]. Magyar onkologia, 2002, Volume: 46, Issue:2 Topics: Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene	2002
[The current state of hormonal prevention of coronary heart disease in menopausal women]. Revista espanola de cardiologia, 2003, Volume: 56, Issue:1 Topics: Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2003
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. The New England journal of medicine, 2003, Feb-13, Volume: 348, Issue:7 Topics: Bone and Bones; Breast; Breast Neoplasms; Central Nervous System; Coronary Disease; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Urogenital System	2003
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 125, Issue:1 Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors	2005
[Effects of estrogen and selective estrogen receptor modulators on osteoporosis]. Clinical calcium, 2005, Volume: 15, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrogens; Evidence-Based Medicine; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2005
[Menopausal hormone therapy and cardiovascular disease]. Revista espanola de cardiologia, 2006, Volume: 59, Issue:10 Topics: Age Factors; Aged; Breast Neoplasms; Cardiovascular Diseases; Cohort Studies; Coronary Angiography; Coronary Disease; Electrocardiography; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Heart Rate; Humans; Life Style; Mammography; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Time Factors	2006
Gonadal hormone substitutes: effects on the cardiovascular system. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1997, Volume: 7 Suppl 1 Topics: Animals; Coronary Disease; Coronary Vessels; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1997
Preventing heart disease and cancer. What randomized, primary-prevention studies show. Postgraduate medicine, 1999, Oct-15, Volume: 106, Issue:5 Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selenium; Tamoxifen; Vitamin E	1999
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Aged; Breast Neoplasms; Cholesterol; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Incidence; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Progress in the prevention of breast cancer: concept to reality. The Journal of steroid biochemistry and molecular biology, 2000, Nov-30, Volume: 74, Issue:5 Topics: Bone Density; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Novel agents to modulate oestrogen action. British medical bulletin, 2000, Volume: 56, Issue:3 Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute, 2001, Oct-03, Volume: 93, Issue:19 Topics: Adult; Aged; Bone and Bones; Breast; Breast Neoplasms; Cardiovascular System; Cinnamates; Clinical Trials as Topic; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Heart; Hot Flashes; Humans; Middle Aged; Models, Biological; Organ Specificity; Osteoporosis; Postmenopause; Premenopause; Prospective Studies; Protein Structure, Tertiary; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thrombophilia; Transcription, Genetic	2001
Tamoxifen, raloxifene and the prevention of breast cancer. Minerva endocrinologica, 2002, Volume: 27, Issue:2 Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2002

Trials

11 trial(s) available for raloxifene hydrochloride and Coronary Disease

Article	Year
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Incidence; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Spine	2008
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation, 2009, Feb-24, Volume: 119, Issue:7 Topics: Age Factors; Aged; Blood Pressure; Coronary Disease; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2009
Effects of raloxifene treatment on the phenotype of blood monocytes. Canadian journal of physiology and pharmacology, 2010, Volume: 88, Issue:5 Topics: Aged; Cholesterol; Cholesterol, HDL; Coronary Disease; Cytokines; Female; Fibrinolysis; Flow Cytometry; Humans; L-Selectin; Leukocyte Count; Lipopolysaccharide Receptors; Lipoprotein(a); Middle Aged; Monocytes; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2010
Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial. Journal of women's health (2002), 2010, Volume: 19, Issue:8 Topics: Aspirin; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Placebos; Platelet Aggregation Inhibitors; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome; Venous Thromboembolism	2010
Electrocardiograms of menopausal women with coronary heart disease or at increased risk for its occurrence. The American journal of cardiology, 2010, Dec-01, Volume: 106, Issue:11 Topics: Aged; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Incidence; Menopause; Middle Aged; Prognosis; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators	2010
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. The American journal of cardiology, 2002, Dec-01, Volume: 90, Issue:11 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Estrogen Antagonists; Female; Humans; Myocardial Infarction; Patient Selection; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome	2002
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome	2004
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. The American journal of cardiology, 2006, Feb-15, Volume: 97, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2006
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Thromboembolism	2006
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2008, Volume: 23, Issue:1 Topics: Aged; Coronary Disease; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Spinal Fractures	2008
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:12 Topics: Biomarkers; Blood Coagulation; Blood Pressure; C-Reactive Protein; Carbohydrate Metabolism; Coronary Disease; Double-Blind Method; Estrogen Antagonists; Estrogens; Female; Fibrinolysis; Hormone Replacement Therapy; Humans; Hysterectomy; Middle Aged; Placebos; Postmenopause; Raloxifene Hydrochloride; Risk Factors	1999

Other Studies

20 other study(ies) available for raloxifene hydrochloride and Coronary Disease

Article	Year
The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Animals; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Evidence-Based Medicine; Female; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
On looking at subgroups. Circulation, 2009, Feb-24, Volume: 119, Issue:7 Topics: Adult; Age Factors; Coronary Disease; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2009
Letter by Choi et al regarding article, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors". Circulation, 2009, Oct-27, Volume: 120, Issue:17 Topics: Age Factors; Clinical Trials as Topic; Coronary Disease; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sex Factors; Treatment Outcome	2009
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Serum calcium, phosphorus and cardiovascular events in post-menopausal women. International journal of cardiology, 2011, Jun-16, Volume: 149, Issue:3 Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Phosphorus; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors	2011
[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Hyperaldosteronism; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2003
Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene. Contemporary clinical trials, 2005, Volume: 26, Issue:6 Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Hyperlipidemias; Lipids; Menopause; Middle Aged; Patient Selection; Raloxifene Hydrochloride; Risk Factors; Smoking	2005
Risk-benefit profiles of raloxifene for women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures	2006
Editorial: The SERM of my dreams. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10 Topics: Bone Density; Breast Neoplasms; Coronary Disease; Female; Humans; Osteoporosis; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
[Drug prevention and proper nutrition. Prevention of breast cancer as in coronary heart disease?]. MMW Fortschritte der Medizin, 2007, Feb-15, Volume: 149, Issue:7 Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Coronary artery disease in women--an equal opportunity killer. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:3 Topics: Animals; Coronary Disease; Estrogens; Female; Humans; Male; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Sex Distribution	1998
Anti-estrogens come of age: a pioneer looks back. Journal of the National Cancer Institute, 1998, May-06, Volume: 90, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms	1998
Designer estrogens. Scientific American, 1998, Volume: 279, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen	1998
Coronary heart disease in women, randomized clinical trials, HERS and RUTH. Maturitas, 1998, Nov-30, Volume: 31, Issue:1 Topics: Coronary Disease; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone; Meta-Analysis as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Women's Health	1998
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Archives of internal medicine, 1999, Jul-12, Volume: 159, Issue:13 Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity	1999
Estrogen and atherothrombosis. The American journal of cardiology, 2000, Aug-15, Volume: 86, Issue:4 Topics: Arteriosclerosis; Attitude of Health Personnel; Coronary Disease; Estrogen Antagonists; Estrogens; Female; Hormone Replacement Therapy; Humans; Osteoporosis; Raloxifene Hydrochloride	2000
Design and methods of the Raloxifene Use for The Heart (RUTH) study. The American journal of cardiology, 2001, Aug-15, Volume: 88, Issue:4 Topics: Angina, Unstable; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Selective Estrogen Receptor Modulators	2001
Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstetrics and gynecology, 2001, Volume: 98, Issue:6 Topics: Breast Neoplasms; Coronary Disease; Cost-Benefit Analysis; Decision Support Techniques; Estrogen Antagonists; Female; Health Promotion; Hormone Replacement Therapy; Humans; Life Expectancy; Markov Chains; Middle Aged; Postmenopause; Quality-Adjusted Life Years; Raloxifene Hydrochloride; United States	2001
Hormone replacement therapy trials: an update. Current atherosclerosis reports, 2002, Volume: 4, Issue:2 Topics: Coronary Disease; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Middle Aged; Phytoestrogens; Plant Preparations; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2002
A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA, 2002, Apr-24, Volume: 287, Issue:16 Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrocystic Breast Disease; Hot Flashes; Humans; Hysterectomy; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	2002